OBJECTIVE: Although research has implicated the apolipoprotein E (APOE) epsilon-4 genotype as having a negative effect on neuropsychological outcomes following traumatic brain injury (TBI), the potentially negative role of the epsilon4 allele on TBI outcomes has recently been challenged. In light of this debate, the present study served to examine the role of APOE genotype on neuropsychological outcomes approximately 1 month following mild to moderate TBI in a military population. Because of the well documented role of the APOE-epsilon4 allele in increasing the risk of Alzheimer's disease, we predicted that persons with the APOE-epsilon4 genotype would display relatively greater deficits in cognition than their non-epsilon4 counterparts. METHODS: 78 participants were consecutively recruited following a mild to moderate TBI and were divided into two groups based on the presence or absence of an APOE epsilon4 allele. Groups were comparable on demographic characteristics and psychosocial outcomes. Participants were administered a comprehensive neuropsychological battery. RESULTS: Analyses revealed comparable performances on most neuropsychological measures and better performances by epsilon4 carriers on select measures of attention, executive functioning and episodic memory encoding. Furthermore, differences remained after accounting for the effects of TBI severity. CONCLUSIONS: Evidence from these analyses supports current literature refuting the notion of relatively poorer neuropsychological functioning associated with the APOE-epsilon4 genotype among young adult participants shortly following mild or moderate brain injury. Neuropsychological performance differences by APOE genotype following TBI are discussed in terms of the importance of considering severity of injury, timing of postinjury assessment and possible neurocognitive compensatory mechanisms.
OBJECTIVE: Although research has implicated the apolipoprotein E (APOE) epsilon-4 genotype as having a negative effect on neuropsychological outcomes following traumatic brain injury (TBI), the potentially negative role of the epsilon4 allele on TBI outcomes has recently been challenged. In light of this debate, the present study served to examine the role of APOE genotype on neuropsychological outcomes approximately 1 month following mild to moderate TBI in a military population. Because of the well documented role of the APOE-epsilon4 allele in increasing the risk of Alzheimer's disease, we predicted that persons with the APOE-epsilon4 genotype would display relatively greater deficits in cognition than their non-epsilon4 counterparts. METHODS: 78 participants were consecutively recruited following a mild to moderate TBI and were divided into two groups based on the presence or absence of an APOE epsilon4 allele. Groups were comparable on demographic characteristics and psychosocial outcomes. Participants were administered a comprehensive neuropsychological battery. RESULTS: Analyses revealed comparable performances on most neuropsychological measures and better performances by epsilon4 carriers on select measures of attention, executive functioning and episodic memory encoding. Furthermore, differences remained after accounting for the effects of TBI severity. CONCLUSIONS: Evidence from these analyses supports current literature refuting the notion of relatively poorer neuropsychological functioning associated with the APOE-epsilon4 genotype among young adult participants shortly following mild or moderate brain injury. Neuropsychological performance differences by APOE genotype following TBI are discussed in terms of the importance of considering severity of injury, timing of postinjury assessment and possible neurocognitive compensatory mechanisms.
Authors: F C Crawford; R D Vanderploeg; M J Freeman; S Singh; M Waisman; L Michaels; L Abdullah; D Warden; R Lipsky; A Salazar; M J Mullan Journal: Neurology Date: 2002-04-09 Impact factor: 9.910
Authors: G Friedman; P Froom; L Sazbon; I Grinblatt; M Shochina; J Tsenter; S Babaey; B Yehuda; Z Groswasser Journal: Neurology Date: 1999-01-15 Impact factor: 9.910
Authors: B L Plassman; R J Havlik; D C Steffens; M J Helms; T N Newman; D Drosdick; C Phillips; B A Gau; K A Welsh-Bohmer; J R Burke; J M Guralnik; J C Breitner Journal: Neurology Date: 2000-10-24 Impact factor: 9.910
Authors: D I Graham; S M Gentleman; J A Nicoll; M C Royston; J E McKenzie; G W Roberts; R E Mrak; W S Griffin Journal: Cell Mol Neurobiol Date: 1999-02 Impact factor: 5.046
Authors: S Y Bookheimer; M H Strojwas; M S Cohen; A M Saunders; M A Pericak-Vance; J C Mazziotta; G W Small Journal: N Engl J Med Date: 2000-08-17 Impact factor: 91.245
Authors: Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy Journal: Proc Natl Acad Sci U S A Date: 2003-12-19 Impact factor: 11.205
Authors: Dawn M Schiehser; Dean C Delis; J Vincent Filoteo; Lisa Delano-Wood; S Duke Han; Amy J Jak; Angela I Drake; Mark W Bondi Journal: J Clin Exp Neuropsychol Date: 2011-07 Impact factor: 2.475
Authors: Jesse A Brown; Kevin H Terashima; Alison C Burggren; Linda M Ercoli; Karen J Miller; Gary W Small; Susan Y Bookheimer Journal: Proc Natl Acad Sci U S A Date: 2011-11-21 Impact factor: 11.205
Authors: Victoria C Merritt; Kristina M Lapira; Alexandra L Clark; Scott F Sorg; Madeleine L Werhane; Amy J Jak; Mark W Bondi; Dawn M Schiehser; Lisa Delano-Wood Journal: Arch Clin Neuropsychol Date: 2019-07-26 Impact factor: 2.813
Authors: Lisa M Moran; H Gerry Taylor; Kalaichelvi Ganesalingam; Julie M Gastier-Foster; Jessica Frick; Barbara Bangert; Ann Dietrich; Kathryn E Nuss; Jerome Rusin; Martha Wright; Keith O Yeates Journal: J Neurotrauma Date: 2009-09 Impact factor: 5.269